Biochemical response in HDV patients treated with pegIFNα, BLV with or without pegIFNα, pegIFNλ, and LNF+RTV with or without pegIFNα
| Treatment strategies | Patients (n) | ALT levels (U/L) | Duration of therapy (weeks) | ALT normalisation | ||
| Baseline | During therapy | Off-therapy | ||||
| Week 24 | Week 48 | Week 24 | ||||
| PegIFNα 180 μg QW* | 15 | 90 | 48 | – | 26.7% | 6.7% |
| BLV 2 mg every day mono* | 15 | 84 | 48 | – | 66.6% | 20% |
| BLV 10 mg every day mono* | 15 | 73 | 48 | 60% | 40% | 33% |
| BLV 2 mg every day +IFNα 180 μg QW* | 15 | 70 | 48 | – | 26.7% | 46.7% |
| BLV 10 mg every day +pegIFNα 180 μg QW* | 15 | 78 | 48 | 20% | 26.7% | 33% |
| LNF 50 mg two times per day+RTV 100 mg †two times per day | 12 | – | 24 | 60% | – | – |
| LNF 50 mg two times per day+RTV 100 mg two times per day+pegIFNα 180 μg/QW† | 4 | – | 24 | 78% | – | – |
| PegIFNλ 180 μg QW‡ | 14 | – | 48 | – | 14% | 36% |
| LNF 50 mg two times per day+RTV 100 mg two times per day+pegIFNλ 180 μg QW§ | 26 | 64 | 24 | – | – | – |
*MYR 203 study.
†LOWR-2 Study.
‡LIMT Study.
§LIFT HDV Study, ‘-’:data not published or not presented.
ALT, alanine aminotransferase; BLV, bulevirtide; HDV, hepatitis D virus; LNF, lonafarnib; pegIFNα, pegylated interferon-α; RTV, ritonavir.